Abstract
BACKGROUND Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. METHODS In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a Vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. RESULTS Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a Vitamin K antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P<0.001 for both noninferiority and superiority), and in 16.1% of the patients receiving aspirin, as compared with 9.0% of those receiving placebo (hazard ratio, 1.89; 95% CI, 1.59 to 2.24; P<0.001). Patients in the apixaban group had a lower incidence of death or hospitalization than those in the Vitamin K antagonist group (23.5% vs. 27.4%; hazard ratio, 0.83; 95% CI, 0.74 to 0.93; P = 0.002) and a similar incidence of ischemic events. Patients in the aspirin group had an incidence of death or hospitalization and of ischemic events that was similar to that in the placebo group. CONCLUSIONS In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a Vitamin K antagonist, aspirin, or both.
| Original language | English |
|---|---|
| Pages (from-to) | 1509-1524 |
| Number of pages | 16 |
| Journal | New England Journal of Medicine |
| Volume | 380 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - 2019 Apr 18 |
ASJC Scopus subject areas
- Medicine(all)
Fingerprint
Dive into the research topics of 'Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. / Lopes, Renato D.; Heizer, Gretchen; Aronson, Ronald et al.
In: New England Journal of Medicine, Vol. 380, No. 16, 18.04.2019, p. 1509-1524.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
AU - Lopes, Renato D.
AU - Heizer, Gretchen
AU - Aronson, Ronald
AU - Vora, Amit N.
AU - Massaro, Tyler
AU - Mehran, Roxana
AU - Goodman, Shaun G.
AU - Windecker, Stephan
AU - Darius, Harald
AU - Li, Jia
AU - Averkov, Oleg
AU - Bahit, M. Cecilia
AU - Berwanger, Otavio
AU - Budaj, Andrzej
AU - Hijazi, Ziad
AU - Parkhomenko, Alexander
AU - Sinnaeve, Peter
AU - Storey, Robert F.
AU - Thiele, Holger
AU - Vinereanu, Dragos
AU - Granger, Christopher B.
AU - Alexander, John H.
AU - Hrabar, A. D.
AU - Caccavo, A.
AU - Licheri, A.
AU - Alvarisqueta, A. F.
AU - Abud, A. M.
AU - Estrada, C.
AU - Sueldo, C. P.
AU - Montenegro, E.
AU - Duronto, E. A.
AU - Blanco, F. L.
AU - Berra, F. C.
AU - Ferré Pácora, F. A.
AU - Lopez, G. M.
AU - Calvo, G.
AU - Azize, G. M.
AU - Luquez, H. A.
AU - Ramos, H.
AU - Colombo, H. R.
AU - Guetta, J. N.
AU - Resk, J. H.
AU - Medrano, J. C.
AU - Costabel, J. P.
AU - Carbajales, J.
AU - Schiavi, L. B.
AU - Saggia, L. I.
AU - Oliva, M. A.
AU - Casas, M.
AU - Snitman, M.
AU - Litvak Bruno, M. R.
AU - Cluigt, N.
AU - Vita, N. A.
AU - Guzman, P. N.
AU - Zangroniz, P. D.
AU - Villarreal, R. A.
AU - Bonato, R. R.
AU - Nani, S.
AU - Sassone, S. A.
AU - Macin, S. M.
AU - Arias, V. E.
AU - Alexopoulos, C.
AU - Brieger, D.
AU - Colquhoun, D.
AU - Heddle, W. F.
AU - Podczeck-Schweighofer, A.
AU - Ebner, C.
AU - Scherr, D.
AU - Lang, I. M.
AU - Huber, K.
AU - Guedes, A.
AU - Convens, C.
AU - Cools, F.
AU - Vercammen, J.
AU - Bartunek, J.
AU - Rossenbacker, T.
AU - Pereira, A. H.
AU - Kormann, A. M.
AU - Freitas, A. F.
AU - Fonseca, A. G.T.
AU - de Quadros, A.
AU - Janella, B. L.
AU - Kalil, C. A.A.
AU - Rodrigues, C. S.
AU - Precoma, D. B.
AU - Ramacciotti, E.
AU - Resende, E. S.
AU - Figueiredo, E. L.
AU - Manenti, E. R.
AU - Costa, F. A.D.
AU - Feitosa, G.
AU - Reis, H. J.L.
AU - Ribeiro, H. B.
AU - de Moraes, J. B.M.X.
AU - Dantas, J. M.M.
AU - Nicolau, J. C.
AU - Saraiva, J. F.K.
AU - Reolão, J.
AU - Piegas, L. S.
AU - Oliveira, L. F.A.
AU - Ritt, L. E.F.
AU - Braile, M. C.V.B.
AU - Dracoulakis, M. A.
AU - de Santos, M. O.N.
AU - Leães, P. E.
AU - Filho, P. P.
AU - Rech, R. L.
AU - Ueda, R.
AU - Silvestrini, T. L.
AU - Michalaros, Y. L.
AU - Manolova, A.
AU - Mihov, A. K.
AU - Yatseva, B.
AU - Velikov, C.
AU - Raev, D. H.
AU - Markov, D.
AU - Vassilev, D.
AU - Georgiev, E.
AU - Benov, H. O.
AU - Daskalov, I.
AU - Petrov, I. P.
AU - Milanova, M.
AU - Shehova-Yankova, N. S.
AU - Lazov, P. V.
AU - Beleva, S.
AU - Marchev, S. T.
AU - Gelev, V. L.
AU - Tyrrell, B.
AU - Wong, B.
AU - Dion, D.
AU - LaFlamme, D.
AU - Rupka, D. W.
AU - Shukla, D.
AU - Sabbah, E.
AU - Nadra, I. J.
AU - Bata, I.
AU - Cherry, J. M.
AU - Toleva, O.
AU - Dehghani, P.
AU - Vijayaraghavan, R.
AU - Welsh, R.
AU - Bagur, R.
AU - Labonte, R. E.
AU - Vizel, S.
AU - Fort, S.
AU - Huynh, T.
AU - Quan, V. H.
AU - Pesant, Y.
AU - Isaza, D.
AU - Accini Mendoza, J. L.
AU - Gomez, J. E.
AU - Jaramillo Gomez, N. I.
AU - Knezevic, A.
AU - Ruzic, A.
AU - Horvat, D.
AU - Milicic, D.
AU - Selthofer-Relatic, K.
AU - Pesek, K.
AU - Pravecek, M. K.
AU - Kovacic, M.
AU - Manola, S.
AU - Persic, V.
AU - Alan, D.
AU - Belohlavek, J.
AU - Larsen, C. T.
AU - Brønnum-Schou, J.
AU - Veien, K. T.
AU - Christensen, L. S.
AU - Maeng, M.
AU - Steffensen, R.
AU - Angoulvant, D.
AU - Beygui, F.
AU - Range, G.
AU - Cayla, G.
AU - Aupetit, J. F.
AU - Elbaz, M.
AU - Delarche, N.
AU - Meneveau, N.
AU - Ghanem, A.
AU - Hagendorff, A.
AU - Wilke, A.
AU - Hummel, A.
AU - Axthelm, C.
AU - Kadel, C.
AU - Langer, C.
AU - Stellbrink, C.
AU - Jacobshagen, C.
AU - Gross, C. M.
AU - Blessing, E. E.B.
AU - Minden, H. H.
AU - Bogossian, H.
AU - Wienbergen, H.
AU - Ebelt, H.
AU - Dreger, H.
AU - Ince, H.
AU - Akin, I.
AU - Eitel, I.
AU - Kreis, I.
AU - Appel, K. F.
AU - Maier, L.
AU - Bergmann, M.
AU - Moser, M.
AU - Toursarkissian, N.
AU - Menck, N.
AU - Ritter, O.
AU - Bernhardt, P.
AU - Nordbeck, P.
AU - Stöhring, R.
AU - Schwinger, R.
AU - Braun-Dullaeus, R. C.
AU - Maier, S. K.G.
AU - Schellong, S.
AU - Steiner, S.
AU - Rudolph, T.
AU - Dengler, T. J.
AU - Geisler, T.
AU - Rauch-Kröhnert, U.
AU - Jung, W.
AU - Jungmair, W.
AU - Komócsi, A.
AU - Papp, A.
AU - Vértes, A.
AU - Mohácsi, A.
AU - Herczeg, B.
AU - Merkely, B.
AU - Dézsi, C. A.
AU - Kis, E.
AU - Lakatos, F.
AU - Kerecsen, G.
AU - Piros, G. A.
AU - Takács, J.
AU - Tomcsányi, J.
AU - Keltai, K.
AU - Kovács, Z.
AU - Mathur, A.
AU - Baxi, H. A.
AU - Narendra, J.
AU - Gupta, J.
AU - Kumbla, M.
AU - Jamwal, N. K.
AU - Arora, P.
AU - Katz, A.
AU - Shotan, A.
AU - Schiff, E.
AU - Freedberg, N. A.
AU - Amir, O.
AU - Hussein, O.
AU - Kracoff, O. H.
AU - Alcalai, R.
AU - Adawi, S. Y.
AU - Viskin, S.
AU - Hayek, T.
AU - Hasin, Y.
AU - Rozenman, Y.
AU - Nam, C. W.
AU - Lee, C. W.
AU - Choi, D. J.
AU - Jeon, D. S.
AU - Park, H. W.
AU - Son, J. W.
AU - Jeong, J. O.
AU - Cha, K. S.
AU - Oh, S.
AU - Rha, S. W.
AU - Park, Y. H.
AU - On, Y. K.
AU - Bazzoni Ruiz, A. E.
AU - Valdespino, A. R.
AU - Castro Montes, B. E.
AU - Ramos Lopez, G. A.
AU - Llamas Esperón, G. A.
AU - Solache, G.
AU - Macías García, J. S.
AU - Leiva-Pons, J. L.
AU - De Los Rios Ibarra, M. O.
AU - Willems, F. F.
AU - Beyerbacht, H. P.
AU - van de Wal, R.
AU - Hysing, J.
AU - Lappegard, K. T.
AU - Vinge, L. E.
AU - Halvorsen, S.
AU - Pönitz, V.
AU - Chavez Ayala, C. A.
AU - Medina Palomino, F. A.
AU - Garcia Matheus, J. C.
AU - Włodarczak, A.
AU - Lubinski, A.
AU - Czarnecka, D.
AU - Wojciechowski, D.
AU - Skonieczny, G.
AU - Kasprzak, J. D.
AU - Wranicz, J. K.
AU - Szachniewicz, J.
AU - Kincel, K. K.
AU - Zmudka, K.
AU - Lesiak, M.
AU - Piekarski, M.
AU - Wujkowski, M.
AU - Lica-Gorzynska, M.
AU - Miekus, P.
AU - Feusette, P.
AU - Bartkowiak, R.
AU - Korzeniak, R.
AU - Sinkiewicz, W.
AU - Musial, W.
AU - Krolikowski, Z.
AU - Gaspar, A.
AU - Pinto, F.
AU - Almeida, F.
AU - Martinez, J.
AU - Brandão, L.
AU - Santos, L. M.
AU - Mateus, P.
AU - Monteiro, P.
AU - Pernencar, S.
AU - Mornoş, C.
AU - Olinic, D. M.
AU - Zdrenghea, D. T.
AU - Ortan, F. O.
AU - Cinteza, M.
AU - Popescu, M.
AU - Voicu, O.
AU - Todea, S. B.F.
AU - Babes, V.
AU - Vishnevskiy, A. Y.
AU - Kuimov, A. D.
AU - Duplyakov, D. V.
AU - Kosmacheva, E.
AU - Pokushalov, E.
AU - Gordeev, I. G.
AU - Zrazhevskiy, K. N.
AU - Sorokin, L. A.
AU - Ermoshkina, L. G.
AU - Zykov, M. V.
AU - Ruda, M. Y.
AU - Bulashova, O.
AU - Smolenskaya, O. G.
AU - Orlikova, O. V.
AU - Grishaev, S. L.
AU - Shalaev, S. V.
AU - Boldueva, S. A.
AU - Kuznetsov, V.
AU - Makukhin, V.
AU - Kostenko, V.
AU - Shvarts, Y.
AU - Kobalava, Z. D.
AU - Selakovic, A.
AU - Tosic, B. P.
AU - Sakac, D. B.
AU - Pavlovic, M.
AU - Dekleva, M.
AU - Tasic, N. M.
AU - Hinic, S.
AU - Jozic, T.
AU - Potpara, T.
AU - Dzupina, A.
AU - Pella, D.
AU - Majercak, I.
AU - Striezova, I.
AU - Fedacko, J.
AU - Gonsorcik, J.
AU - Fecik, J.
AU - Selecky, J.
AU - Antalik, L.
AU - Hranai, M.
AU - Gocar, M.
AU - Kokles, M.
AU - Oriesek, R.
AU - Regueiro, A.
AU - Ibánez, B.
AU - Djurovic, D. P.
AU - Gutierrez Ibañes, E.
AU - Ridocci-Soriano, F.
AU - Diaz Fernandez, J.
AU - Artaecheverria Zuazo, J. J.
AU - Escudier Villa, J. M.
AU - Nuñez Villota, J.
AU - Sanmartin Fernandez, M.
AU - Chinchurreta Capote, P. A.
AU - Muñoz Aguilera, R.
AU - Vera Ripoll, T.
AU - Mainar Tello, V.
AU - Björklund, F.
AU - Jensen, J.
AU - Andersson, J.
AU - Lauermann, J.
AU - Hamid, M.
AU - Angerås, O.
AU - Fischer, T. A.
AU - Yagensky, A. V.
AU - Goloborodko, B. I.
AU - Kyrychenko, I. I.
AU - Vakaliuk, I. P.
AU - Kovalskyy, I.
AU - Rishko, M. V.
AU - Sydor, N.
AU - Karpenko, O. I.
AU - Parkhomenko, O. M.
AU - Koval, O. A.
AU - Godlevska, O.
AU - Zhurba, S.
AU - Maslovskyi, V. Y.
AU - Netiazhenko, V. Z.
AU - Tashchuk, V. K.
AU - Shcherbak, V. P.
AU - Tseluyko, V. I.
AU - Cooke, A.
AU - Wrigley, B.
AU - Francis, C. M.
AU - Barr, C.
AU - Gorog, D. A.
AU - Lip, G. Y.H.
AU - Irving, J.
AU - Mills, J.
AU - Levy, T.
AU - Cheema, A. A.
AU - Salacata, A. S.
AU - Tenaglia, A. N.
AU - Meholick, A. W.
AU - Vedere, A. R.
AU - Patrello, A. J.
AU - Spaedy, A.
AU - Martin, A. C.
AU - Holland, B. H.
AU - Duffy, B. K.
AU - Schuler, B.
AU - Treasure, C. B.
AU - Paraboschi, C.
AU - Pickett, C. A.
AU - Rowan, C. J.
AU - Longnecker, C. R.
AU - Hess, C. N.
AU - Hinchman, D. A.
AU - Schneider, D. J.
AU - Murdock, D. K.
AU - Baldwin, D. E.
AU - Flores, E. A.
AU - Sirulnick, E. J.
AU - Ahmad, F.
AU - Aggarwala, G.
AU - Dhar, G.
AU - Kichura, G. M.
AU - Turitto, G.
AU - Sampognaro, G. C.
AU - Sharma, G. K.
AU - Chandna, H.
AU - Truong, H. T.D.
AU - Poock, J.
AU - Walia, J. S.
AU - Zelenka, J. T.
AU - Amin, J. K.
AU - Foucauld, J.
AU - Chambers, J.
AU - Abbott, J. D.
AU - Strobel, J. S.
AU - Dy, J. R.
AU - Nour, K. A.
AU - Sullenberger, L. E.
AU - Younis, L. T.
AU - Gonzales, L.
AU - Chane, M.
AU - Foster, M. T.
AU - King, M. Y.
AU - Grabarczyk, M. A.
AU - Izzo, M. R.
AU - Leesar, M. A.
AU - Bernabei, M. A.
AU - Cavender, M. D.
AU - Janik, M. J.
AU - Buchbinder, M.
AU - Arcarese, M.
AU - Yeh, M.
AU - Sheth, M. J.
AU - Sinno, M. C.
AU - Shoukfeh, M. F.
AU - Alhaddad, M.
AU - Ranadive, N. V.
AU - Jaffrani, N. A.
AU - Little, N. K.
AU - Shammas, N.
AU - Assi, N. A.
AU - Almousalli, O.
AU - Chan, P.
AU - Horwitz, P. A.
AU - Rozeman, P. A.
AU - Singh, P.
AU - Aggarwal, R.
AU - Gopinathannair, R.
AU - Manshadi, R.
AU - Korabathina, R.
AU - Gilmore, R. M.
AU - Feldman, R. B.
AU - Schnitzler, R. N.
AU - Harrison, R. W.
AU - Gandhi, S. N.
AU - Graham, S.
AU - Krueger, S. K.
AU - Jones, S. E.
AU - Rowe, S. K.
AU - Bazaz, S. B.
AU - Haddad, T. M.
AU - Povsic, T. J.
AU - Badami, U. A.
AU - Abernethy, W. B.
AU - Mirza, Z. A.
N1 - Funding Information: The trial was designed and led by an academic steering committee whose members were respon- sible for the conduct of the trial. The Duke Clinical Research Institute (DCRI, Durham, NC) was the academic coordinating center. The trial was sponsored by Bristol-Myers Squibb and Pfizer. The trial protocol (available with the full text of this article at NEJM.org) and all subsequent amendments were approved by national regulatory agencies in participating countries and by institutional review boards or ethics committees at participating sites. An independent data and safety monitoring board reviewed unblinded patient-level data at regular intervals during the trial. Although Bristol-Myers Squibb assisted with data management, all the statistical analyses were performed independently at the DCRI. The initial draft of the manuscript was written by the first author and revised on the basis of comments from the other authors. All the authors vouch for the adherence of the trial to the protocol, and the first, second, and last authors vouch for the accuracy and completeness of the data and analysis. No one who is not an author contributed to writing the manuscript. The committee members and participating investigators are listed in the Supplementary Appendix, available at NEJM.org. Publisher Copyright: © 2019 Massachusetts Medical Society.
PY - 2019/4/18
Y1 - 2019/4/18
N2 - BACKGROUND Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. METHODS In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a Vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. RESULTS Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a Vitamin K antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P<0.001 for both noninferiority and superiority), and in 16.1% of the patients receiving aspirin, as compared with 9.0% of those receiving placebo (hazard ratio, 1.89; 95% CI, 1.59 to 2.24; P<0.001). Patients in the apixaban group had a lower incidence of death or hospitalization than those in the Vitamin K antagonist group (23.5% vs. 27.4%; hazard ratio, 0.83; 95% CI, 0.74 to 0.93; P = 0.002) and a similar incidence of ischemic events. Patients in the aspirin group had an incidence of death or hospitalization and of ischemic events that was similar to that in the placebo group. CONCLUSIONS In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a Vitamin K antagonist, aspirin, or both.
AB - BACKGROUND Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. METHODS In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a Vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. RESULTS Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a Vitamin K antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P<0.001 for both noninferiority and superiority), and in 16.1% of the patients receiving aspirin, as compared with 9.0% of those receiving placebo (hazard ratio, 1.89; 95% CI, 1.59 to 2.24; P<0.001). Patients in the apixaban group had a lower incidence of death or hospitalization than those in the Vitamin K antagonist group (23.5% vs. 27.4%; hazard ratio, 0.83; 95% CI, 0.74 to 0.93; P = 0.002) and a similar incidence of ischemic events. Patients in the aspirin group had an incidence of death or hospitalization and of ischemic events that was similar to that in the placebo group. CONCLUSIONS In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a Vitamin K antagonist, aspirin, or both.
UR - http://www.scopus.com/inward/record.url?scp=85063740593&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1817083
DO - 10.1056/NEJMoa1817083
M3 - Article
C2 - 30883055
AN - SCOPUS:85063740593
VL - 380
SP - 1509
EP - 1524
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 16
ER -